Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 371


JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma.

Titz B, Lomova A, Le A, Hugo W, Kong X, Ten Hoeve J, Friedman M, Shi H, Moriceau G, Song C, Hong A, Atefi M, Li R, Komisopoulou E, Ribas A, Lo RS, Graeber TG.

Cell Discov. 2016 Sep 6;2:16028. doi: 10.1038/celldisc.2016.28. eCollection 2016.


The pharmacogenomics of drug resistance to protein kinase inhibitors.

Gillis NK, McLeod HL.

Drug Resist Updat. 2016 Sep;28:28-42. doi: 10.1016/j.drup.2016.06.008. Epub 2016 Jul 5.


Pembrolizumab for the treatment of advanced melanoma.

Burns MC, O'Donnell A, Puzanov I.

Expert Opin Orphan Drugs. 2016;4(8):867-873. Epub 2016 Jun 7.


Evaluating cost benefits of combination therapies for advanced melanoma.

Jensen IS, Zacherle E, Blanchette CM, Zhang J, Yin W.

Drugs Context. 2016 Jul 15;5:212297. doi: 10.7573/dic.212297. eCollection 2016.


Endoplasmic reticulum stress-induced autophagy determines the susceptibility of melanoma cells to dabrafenib.

Ji C, Zhang Z, Chen L, Zhou K, Li D, Wang P, Huang S, Gong T, Cheng B.

Drug Des Devel Ther. 2016 Aug 4;10:2491-8. doi: 10.2147/DDDT.S112740. eCollection 2016.


An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI.

Cancer Cell. 2016 Sep 12;30(3):485-98. doi: 10.1016/j.ccell.2016.06.024. Epub 2016 Aug 11.


Novel melanoma therapy.

Hsueh EC, Gorantla KC.

Exp Hematol Oncol. 2016 Aug 8;5:23. doi: 10.1186/s40164-016-0054-1. eCollection 2015. Review.


Efficacy of Tumor-Targeting Salmonella A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model.

Yamamoto M, Zhao M, Hiroshima Y, Zhang Y, Shurell E, Eilber FC, Bouvet M, Noda M, Hoffman RM.

PLoS One. 2016 Aug 8;11(8):e0160882. doi: 10.1371/journal.pone.0160882. eCollection 2016.


Update on use of aldesleukin for treatment of high-risk metastatic melanoma.

Amaria RN, Reuben A, Cooper ZA, Wargo JA.

Immunotargets Ther. 2015 Apr 7;4:79-89. doi: 10.2147/ITT.S61590. eCollection 2015. Review.


Genomic diversity of colorectal cancer: Changing landscape and emerging targets.

Ahn DH, Ciombor KK, Mikhail S, Bekaii-Saab T.

World J Gastroenterol. 2016 Jul 7;22(25):5668-77. doi: 10.3748/wjg.v22.i25.5668. Review.


Malignant Melanoma.

Perera E, Gnaneswaran N, Jennens R, Sinclair R.

Healthcare (Basel). 2013 Dec 20;2(1):1-19. doi: 10.3390/healthcare2010001. Review.


A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib.

Sinnberg T, Makino E, Krueger MA, Velic A, Macek B, Rothbauer U, Groll N, Pötz O, Czemmel S, Niessner H, Meier F, Ikenberg K, Garbe C, Schittek B.

EBioMedicine. 2016 Jun;8:132-49. doi: 10.1016/j.ebiom.2016.04.037. Epub 2016 May 1.


Targeting MAPK Signaling in Age-Related Macular Degeneration.

Kyosseva SV.

Ophthalmol Eye Dis. 2016 Jun 23;8:23-30. doi: 10.4137/OED.S32200. eCollection 2016. Review.


The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib.

Medina TM, Lewis KD.

Onco Targets Ther. 2016 Jun 22;9:3739-52. doi: 10.2147/OTT.S86774. eCollection 2016. Review.


BRAF-Directed Therapy in Metastatic Colorectal Cancer.

Korphaisarn K, Kopetz S.

Cancer J. 2016 May-Jun;22(3):175-8. doi: 10.1097/PPO.0000000000000189.


Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.

Rajkumar S, Watson IR.

Br J Cancer. 2016 Jul 12;115(2):145-55. doi: 10.1038/bjc.2016.195. Epub 2016 Jun 23.


A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma.

Lo MC, Paterson A, Maraka J, Clark R, Goodwill J, Nobes J, Garioch J, Moncrieff M, Rytina E, Igali L.

Br J Cancer. 2016 Jul 12;115(2):223-7. doi: 10.1038/bjc.2016.106. Epub 2016 Jun 23.


The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.

Peh J, Fan TM, Wycislo KL, Roth HS, Hergenrother PJ.

Mol Cancer Ther. 2016 Aug;15(8):1859-69. doi: 10.1158/1535-7163.MCT-16-0025. Epub 2016 Jun 13.


Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.

Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P, Ariyan CE, Brady MS, Coit DG, Bogatch K, Callahan MK, Wolchok JD, Carvajal RD, Postow MA.

Oncologist. 2016 Jul;21(7):848-54. doi: 10.1634/theoncologist.2015-0522. Epub 2016 Jun 10.


CRAF R391W is a melanoma driver oncogene.

Atefi M, Titz B, Tsoi J, Avramis E, Le A, Ng C, Lomova A, Lassen A, Friedman M, Chmielowski B, Ribas A, Graeber TG.

Sci Rep. 2016 Jun 8;6:27454. doi: 10.1038/srep27454.

Items per page

Supplemental Content

Write to the Help Desk